Veru (NASDAQ:VERU) Posts Earnings Results

Veru (NASDAQ:VERU) posted its quarterly earnings data on Wednesday. The company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.47) by $0.21, FiscalAI reports.

Here are the key takeaways from Veru’s conference call:

• FDA meeting gave regulatory clarity for enobosarm with two potential approval pathways (≥5% incremental placebo‑corrected weight loss at 52 weeks or demonstration of clinically meaningful preservation/improvement in physical function), and confirmed enobosarm 3 mg as an acceptable dose for development.
• Veru plans to start the double‑blind Phase 2b PLATEAU study this quarter in ~200 patients ≥65 years on semaglutide, with a 68‑week primary endpoint for percent change in body weight and an interim DEXA analysis of lean/fat mass at 34 weeks.
• The FDA’s Dec 2025 decision that total hip BMD by DEXA can be a validated surrogate endpoint could provide an alternate approval route for enobosarm in postmenopausal women on GLP‑1 therapy, and preclinical data show enobosarm increases BMD.
• Balance sheet improved after an October 2025 underwritten offering: net proceeds ~$23.4 million and cash, cash equivalents and restricted cash of $33.0 million, which management says should fund operations through the PLATEAU interim analysis.
• The company remains unprofitable with a Q1 net loss of $5.3 million (26¢/share), negative operating cash flow (used $6.2 million in the quarter), and continued development risk ahead of pivotal studies.

Veru Trading Up 2.2%

VERU traded up $0.05 during midday trading on Wednesday, hitting $2.36. 60,120 shares of the company traded hands, compared to its average volume of 122,250. The company has a market capitalization of $37.88 million, a price-to-earnings ratio of -1.07 and a beta of -1.42. The business has a 50 day simple moving average of $2.43 and a two-hundred day simple moving average of $3.11. Veru has a 52-week low of $2.10 and a 52-week high of $7.40.

Institutional Trading of Veru

Several hedge funds have recently made changes to their positions in the company. Northwestern Mutual Wealth Management Co. purchased a new stake in Veru during the third quarter worth about $38,000. XTX Topco Ltd purchased a new stake in Veru during the 2nd quarter worth approximately $49,000. Bank of America Corp DE lifted its holdings in Veru by 5.5% during the 2nd quarter. Bank of America Corp DE now owns 185,669 shares of the company’s stock worth $108,000 after buying an additional 9,637 shares in the last quarter. Jacobs Levy Equity Management Inc. purchased a new position in Veru in the 3rd quarter valued at approximately $110,000. Finally, Raymond James Financial Inc. grew its stake in shares of Veru by 48.3% in the second quarter. Raymond James Financial Inc. now owns 206,405 shares of the company’s stock worth $120,000 after acquiring an additional 67,178 shares in the last quarter. Hedge funds and other institutional investors own 47.16% of the company’s stock.

Analyst Ratings Changes

VERU has been the subject of a number of research reports. Oppenheimer reaffirmed an “outperform” rating on shares of Veru in a report on Thursday, December 18th. Canaccord Genuity Group assumed coverage on shares of Veru in a report on Thursday, December 18th. They set a “buy” rating and a $25.00 target price for the company. Wall Street Zen lowered shares of Veru from a “hold” rating to a “sell” rating in a report on Saturday, January 31st. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Veru in a research report on Wednesday, January 21st. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Veru presently has an average rating of “Moderate Buy” and a consensus price target of $22.50.

About Veru

Veru Inc is a clinical-stage biopharmaceutical company headquartered in Miami, Florida. The company is dedicated to the development and commercialization of novel therapies in the fields of oncology and infectious disease. Veru’s research strategy centers on advancing small-molecule and biologic candidates through clinical trials, leveraging its in-house manufacturing and formulation capabilities as well as strategic partnerships to support late-stage development.

The company’s lead product candidate is sabizabulin (VERU-111), an oral, microtubule-disrupting agent undergoing pivotal trials for indications that include metastatic castration-resistant prostate cancer and hospitalized patients with severe COVID-19.